Patterns of FIRST recurrence of stage IIIC1 endometrial cancer with no PARAAORTIC nodal assessment.
Alessia Aloisi, João Miguel Casanova, Jill H Tseng...
https://pubmed.ncbi.nlm.nih.gov/30286945/Actively Recruiting
Led by Fondazione IRCCS Istituto Nazionale dei Tumori, Milano · Updated on 2022-08-17
500
Participants Needed
1
Research Sites
104 weeks
Total Duration
Researchers are studying the role of small-volume lymph node disease, including isolated tumor cells and micrometastases, in patients with early stage endometrial or cervical cancer who undergo a sentinel lymph node SLN procedure. The purpose is to collect and analyze data on the type and amount of lymph node disease, treatment decisions, and cancer outcomes such as disease-free survival, overall survival, and recurrence rates. Understanding these factors may help identify which patients require additional treatment based on their lymph node status. Participants in this observational study have early stage endometrial or cervical cancer and undergo sentinel lymph node biopsy, with or without lymphadenectomy. The lymph nodes are pathologically evaluated using ultra-staging or a nucleic acid amplification method to detect metastases. The study includes patients with lymph node metastases of varying sizes, including macrometastases and small-volume disease such as micrometastasis and isolated tumor cells. During the study, researchers will track cancer outcomes like survival and recurrence for about three years and monitor the use of additional therapies for up to six months. Data collection involves evaluating lymph node disease type and volume, treatment choices, and patient follow-up. The study is sponsored by Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, and aims to improve understanding of how lymph node findings affect treatment decisions and outcomes in uterine cancers.
CONDITIONS
The Role of Micrometastasis and Isolated Tumor Cells (ITCs) in Endometrial and Cervical Cancer. A Multicenter Study.
F
Fabio Martinelli, MD
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Lead Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Day of procedure
Participants undergo sentinel lymph node biopsy with possible lymphadenectomy to evaluate lymph nodal disease.
1 visit (in-person)
Duration - Approximately 3 years
Participants are monitored for disease-free survival, overall survival, and recurrence over time.
Follow-up visits as per routine clinical care over study duration
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Alessia Aloisi, João Miguel Casanova, Jill H Tseng...
https://pubmed.ncbi.nlm.nih.gov/30286945/Myriam Delomenie, Hélène Bonsang-Kitzis, Anne-Sophie Bats...
https://pubmed.ncbi.nlm.nih.gov/31450214/Benedetta Guani, Maxence Dorez, Laurent Magaud...
https://pubmed.ncbi.nlm.nih.gov/30833435/Atanas Ignatov, Christin Lebius, Tanja Ignatov...
https://pubmed.ncbi.nlm.nih.gov/31345606/N R Gómez-Hidalgo, P T Ramirez, B Ngo...
https://pubmed.ncbi.nlm.nih.gov/31863354/Andra Nica, Lilian T Gien, Sarah Elizabeth Ferguson...
https://pubmed.ncbi.nlm.nih.gov/31871114/Marie Plante, Jonathan Stanleigh, Marie-Claude Renaud...
https://pubmed.ncbi.nlm.nih.gov/28577885/Sabrina Piedimonte, Lara Richer, Luis Souhami...
https://pubmed.ncbi.nlm.nih.gov/30353577/D Cibula, N R Abu-Rustum, L Dusek...
https://pubmed.ncbi.nlm.nih.gov/22120175/Emily Anne Goebel, Jessica D St Laurent, Marisa R Nucci...
https://pubmed.ncbi.nlm.nih.gov/31818860/Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Lead Sponsor